2023-11-12 00:10:29
Dementia is a problem that is increasing around the world. To help in the treatment of patients, the Federal Commission for the Protection against Health Risks (Cofepris) authorized a new drug against Alzheimer’s. Furthermore, it is not the only novelty because there are other drugs that received the go-ahead to begin being marketed.
Over the last decades, life expectancy has increased throughout the world. Although in the first instance it is a favorable aspect, in the end it does not mean that living longer is entirely positive.
New drug against Alzheimer’s authorized
One of the problems of extending life has been the increase in the incidence of diseases such as Alzheimer. In Mexico there are no official records but it is estimated that there are at least one million 300 thousand people with this condition. While in the future the figure is expected to even double.
From the above, the Cofepris released the most recent biweekly therapeutic expansion report. The authorization of 166 new health supplies during the first half of October stands out.
Among the new records there are 28 that correspond to medications. One of the most attractive points is that a new drug against Alzheimer’s and it is the molecule rivastigmine in oral solution format.
#Cofepris approves 166 new supplies, including a new molecule for Alzheimer’s dementia.
???? pic.twitter.com/jrGbFqrhNL
— COFEPRIS (@COFEPRIS) November 10, 2023
Main symptoms of Alzheimer’s
The probability of suffering from this condition increases as a person ages. Although cases have also been reported in young adults. The main symptom is memory loss, although there are also other warning signs.
Cognitive impairment. Temporo-spatial disorientation. Difficulty expressing yourself. Difficulty carrying out activities of daily living.
Other drugs that were approved by Cofepris
Fusidic acid for topical treatment of bacterial conjunctivitis. Diosmectite suspension for diarrhea in children over two years of age and adults. Plerixafor to enhance the mobilization of hematopoietic stem cells to the peripheral blood. Tranexamic acid in intravenous solution as an adjuvant in the treatment of postpartum hemorrhage.
Likewise, they authorized three new clinical trialsamong which stand out: one aimed at evaluating the quality and effectiveness of a treatment for large B-cell lymphoma, and another aimed at the treatment of melanoma.
The report also includes the approval of 135 new medical devices, 53 of which are aimed at healthcare, such as hearing aids, cardiac electrophysiology catheters, embryo transfer and cardiac mapping, as well as absorbable synthetic bone substitutes, among others.
Within this set of devices, 40 new medical equipment is contemplated, such as coagulation analyzers and immunological tests, as well as surgical medical instruments. Likewise, 42 new devices were authorized for the diagnosis and detection of diseases such as hepatitis B and Zika.
Also read:
ENARM 2023: This specialty chose the second best national score
Veracruz doctor is accused of shooting a minor because he mistook him for an assailant
The best pharmacy chains in Mexico (2023 edition)
#Cofepris #authorizes #drug #Alzheimers